What does this research mean for the field?

Patients with HR+/HER2- metastatic breast cancer have a high unmet need for effective treatments following endocrine therapy, with nearly one-third not surviving to receive the second line of post endocrine therapy treatment. Novelty: ClaimNovelty.NOVEL_FINDING. Consensus alignment: ConsensusAlignment.CHALLENGES_CONSENSUS.

What question did this study set out to answer?

To assess treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer following endocrine therapy.

February 19, 2026Clinical Cancer Research

Abstract PS1-10-23: Real-world analysis of unmet need among patients in the US with HR+/HER2- mBC following endocrine therapy

View Full Paper

Ask AI

Bookmark

Authors

JOJ. A. O'ShaughnessyTexas Oncology MRM K RehnquistGilead Sciences (United States)NSN. SadetskyGilead Sciences (United States)

Discussion

Member takes

Implication

Retrospective cohort analysis reveals limited survival outcomes in US women with HR+/HER2- mBC post endocrine therapy, suggesting an urgent need for new treatments.

Key Points

To assess treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer following endocrine therapy.
Retrospective observational cohort study design
Utilized data from the Flatiron Health Research Database
Included women aged ≥ 18 with HR+/HER2- mBC post endocrine therapy from 2015 to 2024
Analyzed patient characteristics, treatment patterns, and survival outcomes using Kaplan-Meier methods
5012 patients included with a median age of 63 years at diagnosis
Median overall survival from start of first post endocrine therapy treatment was 13.4 months
30% of patients did not survive to the next treatment
Chemotherapy was the primary treatment choice, with capecitabine being the most common
Survival decreased with each subsequent treatment line, indicating high unmet needs.

Cite This Study

O'Shaughnessy et al. (2026) studied this question.

synapsesocial.com/papers/6996a898ecb39a600b3ef6fa https://doi.org/10.1158/1557-3265.sabcs25-ps1-10-23

View Full Paper

Ask AI

Bookmark

Implication

Retrospective cohort analysis reveals limited survival outcomes in US women with HR+/HER2- mBC post endocrine therapy, suggesting an urgent need for new treatments.

Abstract PS1-10-23: Real-world analysis of unmet need among patients in the US with HR+/HER2- mBC following endocrine therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Abstract PS1-10-23: Real-world analysis of unmet need among patients in the US with HR+/HER2- mBC following endocrine therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider